Product Description
A synthetic small molecule and peptidomimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/birinapant)
Mechanisms of Action: IAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TetraLogic
Company Location: PAOLI NY 19301
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer|Serous Cystadenocarcinoma|NUT Carcinoma|Cervical Cancer|Head and Neck Cancer|Colorectal Cancer|Mesothelioma|Squamous Cell Carcinoma|Small Cell Lung Cancer|Esophageal Cancer|Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Cholangiocarcinoma|Gastrointestinal Cancer|Preleukemia|Acute Myelomonocytic Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Monocytic Leukemia|Oncology Solid Tumor Unspecified|Juvenile Myelomonocytic Leukemia,|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 1: Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Hepatitis A|Hepatitis B, Chronic|Lymphoma|Oncology Solid Tumor Unspecified|Facial Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Mouth Cancer|Nasopharyngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2019-00175 | P1 |
Terminated |
Squamous Cell Carcinoma|Nasopharyngeal Cancer|Head and Neck Cancer |
2023-11-15 |
|
| 19-C-0041 | P1 |
Recruiting |
Mouth Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Facial Cancer |
2020-10-31 |
|
| BPT-201 | P2 |
Terminated |
Gastrointestinal Cancer|Small Cell Lung Cancer|Cervical Cancer|Ovarian Cancer|NUT Carcinoma|Cholangiocarcinoma|Head and Neck Cancer|Mesothelioma|Squamous Cell Carcinoma|Esophageal Cancer|Colorectal Cancer |
2020-02-17 |
|
| HGSOC | P2 |
Withdrawn |
Peritoneal Cancer|Ovarian Cancer|Serous Cystadenocarcinoma |
2020-02-01 |